Unique ID issued by UMIN | UMIN000037191 |
---|---|
Receipt number | R000042398 |
Scientific Title | Rumination Focused Cognitive-Behavioral Therapy for Treatment-resistant Depression: A Pilot study |
Date of disclosure of the study information | 2019/06/27 |
Last modified on | 2022/09/15 16:45:19 |
Rumination Focused Cognitive-Behavioral Therapy for Treatment-resistant Depression: A Pilot study
RFCBT-Pilot study
Rumination Focused Cognitive-Behavioral Therapy for Treatment-resistant Depression: A Pilot study
Rumination Focused Cognitive-Behavioral Therapy for Treatment-resistant Depression: A Pilot study
Japan |
Treatment-resistant Depression
Psychiatry |
Others
NO
To evaluate safety, efficacy and feasibility of Rumination Focused Cognitive-Behavioral Therapy for Treatment-resistant Depression
Safety,Efficacy
Exploratory
Pragmatic
Phase I,II
1. Baseline reduction score of GRID-Hamilton Depression Rating Scale (GRID-HAMD) at 16wk
2. Drop-out rate
1. Baseline reduction score of GRID-Hamilton Depression Rating Scale (GRID-HAMD) at 28 and 40wk
2. Beck Depression Inventory (BDI-II), Generalized Anxiety Disorder (GAD-7), Ruminative Responses Scale (RRS), Sheehan Disability Scale (SDISS), Cognitive-Behavioral Avoidance Scale (CBAS), Coping Inventory for Stressful Situations (CISS): 0,8,16,28,40 wks
3. Quick Inventory of Depressive Symptomatology (QIDS), Euro-Qol (EQ-5D), Session Rating Scale (SRS) at each session
4. Client satisfaction questionnaire (CSQ-8j): 0, 8,16 wks
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Behavior,custom |
Rumination Focused Cognitive-Behavioral Therapy
20 | years-old | <= |
70 | years-old | >= |
Male and Female
1) having a diagnosis of DSM-IV Major Depressive Disorder confirmed with the SCID
2) have been treated with antidepressants or cognitive behavioral therapy for depression at least 8 weeks up to screening.
3) GRID-HAMD-17>=14
4) can attend session more than 8
5) 20 years old <= age <70 years old
6) can obtain written consent
1) No alcohol or substance use disorder in 12 months prior to the screening
2) No history or concurrent manic episode or psychotic disorders
3) No other primary DSM-IV Axis I Disorders at screening
4) No comorbid of antisocial personality disorder
5) No serious suicidal ideation at screening
6) No organic brain lesions or major cognitive deficits in a year prior to the screening
7) No severe or unstable medical co-morbidities at screening
8) No structured psychotherapy during the intervention.
9) Other relevant reason decided by the CBT principal investigator.
8
1st name | Atsuo |
Middle name | |
Last name | Nakagawa, MD, PhD |
Keio University School of Medicine
Department of Neuropsychiatry
160-8582
Shinanomachi 35, Shinjuku-ku, Tokyo, Japan
03-5363-3235
anakagawa@keio.jp
1st name | Atsuo |
Middle name | |
Last name | Nakagawa, MD, PhD |
Keio University School of Medicine
Department of Neuropsychiatry
160-8582
Shinanomachi 35, Shinjuku-ku, Tokyo, Japan
03-5363-3235
anakagawa@keio.jp
Keio University School of Medicine, Department of Neuropsychiatry
Japan Society for the Promotion of Science
Government offices of other countries
Japan
Keio University School of Medicine
Shinanomachi 35, Shinjuku-ku, Tokyo, Japan
03-3353-1211
med-rinri-jimu@adst.keio.ac.jp
NO
慶應義塾大学医学部・慶應義塾大学病院 (東京都)
Keio University School of Medicine, Department of Neuropsychiatry (Tokyo)
2019 | Year | 06 | Month | 27 | Day |
Unpublished
Completed
2019 | Year | 05 | Month | 21 | Day |
2019 | Year | 06 | Month | 24 | Day |
2019 | Year | 07 | Month | 04 | Day |
2023 | Year | 03 | Month | 31 | Day |
2019 | Year | 06 | Month | 27 | Day |
2022 | Year | 09 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042398